Brief: Zymeworks Unit & Beigene Entered Into Termination Agreement For License And Collaboration Agreement Of Zanidatamab Zovodotin

Zymeworks

21/09/2023 23:17

Sept 21 (Reuters) - Beigene Ltd  6160.HK :
    * ZYMEWORKS - ON SEPT 18, CO'S UNIT & BEIGENE ENTERED INTO
TERMINATION AGREEMENT FOR LICENSE AND COLLABORATION AGREEMENT OF
ZANIDATAMAB ZOVODOTIN
    * ZYMEWORKS INC - TERMINATION AGREEMENT DOES NOT TERMINATE
THE
ZANIDATAMAB LICENSE AND COLLABORATION AGREEMENT
    * ZYMEWORKS - PURSUANT TO TERMINATION AGREEMENT, ZANIDATAMAB
ZOVODOTIN LICENSE & COLLABORATION AGREEMENT IS TERMINATED,
EFFECTIVE AS OF SEPT 18, 2023
    * ZYMEWORKS - TERMINATION DOESN'T RELIEVE PARTIES FROM
OBLIGATIONS
UNDER ZANIDATAMAB ZOVODOTIN LICENSE & COLLABORATION DEAL ACCRUED
PRIOR TO TERMINATION
    * ZYMEWORKS-IN CONNECTION WITH ENTRY INTO TERMINATION, ON
SEPT 18,
2023, CO'S UNIT, BEIGENE ENTERED INTO 3RD AMENDMENT TO LICENSE &
COLLABORATION DEAL
    * ZYMEWORKS-PURSUANT TO AMENDMENT,UNIT ELIGIBLE TO RECEIVE
TIERED
ROYALTIES RANGING HIGH SINGLE DIGIT PERCENTAGES UP TO 19.5% ON
NET SALES OF ZANIDATAMAB

Source text for Eikon:  ID: 
Further company coverage:  6160.HK 

 ((Reuters.Briefs@thomsonreuters.com;))